ID   KB-V1
AC   CVCL_2089
SY   KB-v1; KB-V-1; KBV1
DR   BTO; BTO:0003917
DR   CLO; CLO_0007077
DR   CLDB; cl3009
DR   BioSample; SAMN03151732
DR   ChEMBL-Cells; CHEMBL4295414
DR   ChEMBL-Targets; CHEMBL4296451
DR   DSMZ; ACC-149
DR   DSMZCellDive; ACC-149
DR   PubChem_Cell_line; CVCL_2089
DR   Wikidata; Q54899567
RX   PubMed=3711108;
RX   PubMed=7865904;
RX   PubMed=22118813;
WW   http://www.ott.nih.gov/erma/multidrug-resistant-epidermal-carcinoma-cell-line-kb-v-1
WW   https://iclac.org/wp-content/uploads/Cross-Contaminations_v12_distribution.xlsx
CC   Problematic cell line: Contaminated. Grand-parent cell line (KB) has been shown to be a HeLa derivative.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00373.
CC   Population: African American.
CC   Doubling time: ~50 hours (DSMZ=ACC-149).
CC   Selected for resistance to: ChEBI; CHEBI:27375; Vincaleukoblastine (Vinblastine).
CC   Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18).
CC   Derived from site: In situ; Uterus, cervix; UBERON=UBERON_0000002.
ST   Source(s): DSMZ; PubMed=22118813
ST   Amelogenin: X
ST   CSF1PO: 9,10
ST   D13S317: 12,13.3 (DSMZ)
ST   D13S317: 12,14 (PubMed=22118813)
ST   D16S539: 9,10
ST   D18S51: 16
ST   D19S433: 13,14
ST   D21S11: 27,28
ST   D2S1338: 17
ST   D3S1358: 15,17,18
ST   D5S818: 11,12
ST   D7S820: 8,12
ST   D8S1179: 12,13
ST   FGA: 21
ST   Penta D: 8,15
ST   Penta E: 7,17
ST   TH01: 7
ST   TPOX: 8,12
ST   vWA: 16,18
DI   NCIt; C27677; Human papillomavirus-related cervical adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_2088 ! KB-3-1
SX   Female
AG   30Y6M
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 23
//
RX   PubMed=3711108; DOI=10.1016/S0021-9258(19)57466-X;
RA   Shen D.-W., Cardarelli C., Hwang J., Cornwell M., Richert N., Ishii S.,
RA   Pastan I., Gottesman M.M.;
RT   "Multiple drug-resistant human KB carcinoma cells independently
RT   selected for high-level resistance to colchicine, adriamycin, or
RT   vinblastine show changes in expression of specific proteins.";
RL   J. Biol. Chem. 261:7762-7770(1986).
//
RX   PubMed=7865904;
RA   Zhang X.P., Ritke M.K., Yalowich J.C., Slovak M.L., Ho J.P.,
RA   Collins K.I., Annable T., Arceci R.J., Durr F.E., Greenberger L.M.;
RT   "P-glycoprotein mediates profound resistance to bisantrene.";
RL   Oncol. Res. 6:291-301(1994).
//
RX   PubMed=22118813; DOI=10.1016/j.canlet.2011.09.038;
RA   Krech T., Scheuerer E., Geffers R., Kreipe H.-H., Lehmann U.,
RA   Christgen M.;
RT   "ABCB1/MDR1 contributes to the anticancer drug-resistant phenotype of
RT   IPH-926 human lobular breast cancer cells.";
RL   Cancer Lett. 315:153-160(2012).
//